Fluicell AB

Equities

FLUI

SE0010831321

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:20:42 2024-05-31 EDT			5-day change	1st Jan Change
0.101 ^SEK	-3.81%		-5.16%	-84.02%

05-10	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-08	Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Fluicell AB announced that it has received funding from Almi Invest AB

October 06, 2013

Avalance Biotech announced that it has received an undisclosed amount in funding on October 7, 2013. The transaction involved participation from individual investor, Pär Ribbner and Almi Invest AB.

On October 7, 2013, Avalance Biotech closed the transaction.

Latest news about Fluicell AB

Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-08	CI
Fluicell AB Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Fluicell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Certain Shares of Fluicell AB are subject to a Lock-Up Agreement Ending on 22-APR-2023.	23-04-21	CI
Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Fluicell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-30	CI
Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Fluicell AB Auditor Raises 'Going Concern' Doubt	22-04-25	CI
Fluicell AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
Fluicell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-19	CI
Fluicell AB announced that it expects to receive SEK 23.202065 million in funding	21-09-21	CI
Fluicell AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-20	CI
Fluicell AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-07	CI
Fluicell Launches Biozone 6	21-03-18	CI
Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-24	CI
Fluicell Introduces BioPen FLEX	18-04-26	CI
Fluicell AB has completed an IPO in the amount of SEK 32.7 million.	18-04-17	CI
Fluicell AB has filed an IPO in the amount of SEK 32.7 million.	18-03-15	CI
Fluicell AB Enters Partnership with Cellectricon AB	17-11-07	CI
Fluicell AB announced that it has received funding from Almi Invest AB	13-10-06	CI

Chart Fluicell AB

Duration

Period

More charts

Company Profile

Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâs products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-15 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FLUICELL AB	-84.02%	3.15M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research